TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from PreveCeutical Medical ( (TSE:PREV) ).
PreveCeutical Medical Inc. has announced a new program to develop its Sol-Gel Nose to Brain (N2B) delivery platform for treating Parkinson’s Disease. This program aims to deliver Dopamine and/or L-Dopa directly to the brain, potentially reducing side effects and improving patient outcomes by bypassing the Blood Brain Barrier. The company intends to explore partnerships once proof of concept is established in a preclinical model, underscoring its commitment to cost-effective therapeutic development and positioning itself favorably within the health sciences industry.
More about PreveCeutical Medical
PreveCeutical is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature identical products. The company aims to be a leader in the preventive health sciences sector.
YTD Price Performance: 5.56%
Average Trading Volume: 126,001
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.44M
See more data about PREV stock on TipRanks’ Stock Analysis page.